Cancer Pain - Pipeline Review - H1 2015

Published: June 2015



Global Markets Direct’s, ‘Cancer Pain - Pipeline Review, H1 2015’, provides an overview of the Cancer Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 



  • The report provides a snapshot of the global therapeutic landscape of Cancer Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cancer Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline




Table of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Pain Overview 8
Therapeutics Development 9
Pipeline Products for Cancer Pain - Overview 9
Pipeline Products for Cancer Pain - Comparative Analysis 10
Cancer Pain - Therapeutics under Development by Companies 11
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 15
Cancer Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cancer Pain - Products under Development by Companies 20
Cancer Pain - Products under Investigation by Universities/Institutes 23
Cancer Pain - Companies Involved in Therapeutics Development 24
Amgen Inc. 24
Amorsa Therapeutics Inc. 25
AngioChem Inc. 26
Aphios Corporation 27
AstraZeneca Plc 28
BCN Peptides, S.A. 29
Benitec Biopharma Limited 30
BioDelivery Sciences International, Inc. 31
ChironWells GmbH 32
Daiichi Sankyo Company, Limited 33
Grunenthal GmbH 34
GW Pharmaceuticals Plc 35
Immupharma Plc 36
IntelGenx Corp. 37
Kolon Life Science, Inc. 38
Nektar Therapeutics 39
Neurocentrx Pharma Ltd. 40
Nippon Kayaku Co., Ltd. 41
Northern Light Pharmaceuticals AB 42
Orion Oyj 43
Pain Therapeutics, Inc. 44
Pfizer Inc. 45
Pharmaleads 46
Recordati S.p.A. 47
Sorrento Therapeutics, Inc. 48
Virobay Inc. 49
Winston Pharmaceuticals, Inc. 50
Zynerba Pharmaceuticals, Inc. 51
Cancer Pain - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 62
AMS-410 ER12 - Drug Profile 62
ANG-2002 - Drug Profile 63
BBI-11008 - Drug Profile 64
calpastatin - Drug Profile 65
cebranopadol - Drug Profile 66
crotalphine - Drug Profile 68
DD-04107 - Drug Profile 69
dexmedetomidine hydrochloride - Drug Profile 70
dronabinol - Drug Profile 72
Drug for Cancer Neuropathic Pain - Drug Profile 73
fentanyl - Drug Profile 74
fentanyl citrate - Drug Profile 75
fentanyl citrate - Drug Profile 76
fulranumab - Drug Profile 77
HS-198 - Drug Profile 80
hydromorphone hydrochloride - Drug Profile 81
INT-0028 - Drug Profile 82
IPP-102199 - Drug Profile 83
ketamine hydrochloride ER - Drug Profile 84
KLS-2010 - Drug Profile 85
methadone hydrochloride - Drug Profile 86
nabiximols - Drug Profile 87
Nervarna - Drug Profile 90
NKTR-192 - Drug Profile 92
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 93
PGN-202 - Drug Profile 94
PL-265 - Drug Profile 95
Q-201 - Drug Profile 96
QX-314 - Drug Profile 97
resiniferatoxin - Drug Profile 98
saracatinib difumarate - Drug Profile 99
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 101
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 102
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 103
Small Molecule to Antagonize Chemokine Receptor for Cancer Pain - Drug Profile 104
tanezumab - Drug Profile 105
VBY-825 - Drug Profile 107
zucapsaicin - Drug Profile 108
ZYN-001 - Drug Profile 110
Cancer Pain - Recent Pipeline Updates 111
Cancer Pain - Dormant Projects 122
Cancer Pain - Discontinued Products 126
Cancer Pain - Product Development Milestones 128
Featured News & Press Releases 128
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134